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properties are dynamic in nature. Therapeutic agents 
inhibiting tumor cell reprogramming may have the potential 
to increase the effectiveness of radiotherapy. Moreover, 
monitoring of CSC-related biomarker before and during the 
course of radiotherapy may be able to predict therapy 
response and clinical outcome. 
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Purpose or Objective: This study analyzed whether short-
term death of patients with peripheral stage I NSCLC can be 
predicted reliably to select a sub-group of patients, which 
will not have a benefit from SBRT and which can be referred 
to wait and see. 
 
Material and Methods: 802 patients with early stage NSCLC 
treated with SBRT in 5 institutes for whom information on 
overall survival within the first six months after treatment 
was available were included in this analysis. The probability 
of dying within six months after treatment was modeled by 
multivariate logistic regression; this interval was chosen 
because death of early stage NSCLC is a rare event within six 
months after diagnosis. Model fitting was performed using the 
LASSO method which simultaneously serves to select the 
features most closely related to the outcome. The 
performance of the model that would be achieved on an 
independent dataset was estimated using double 10-fold 
cross validation (CV). Because with CV the estimation of test 
performance depends somewhat on the splitting of the data 
sets, double 10-fold CV was repeated 100 times, resulting in 
1000 models from which the variance in the performance 
measure could be obtained. The variables age, gender, ECOG 
status, operability, FEV1 and Charlson comorbidity index 
(CCI) where considered for model building. 
 
Results: Using different variable combinations for model 
building resulted in different sample sizes and model 
performances (Table 1). Common among all models was the 
identification of the CCI as the most frequently selected and 
thus most important variable predicting six-months death, 
with increasing values predicting higher probability of death. 
Gender was consistently the second-most frequently selected 
variable. Regressing on the individual components of the CCI 
with the LASSO method showed that presence of a second 
solid tumor was the most important predictor, followed by 
various forms of heart disease (Figure 1). Replacing the CCI 
by these individual components in model building confirmed 
the strong relation between the presence of a second tumor 
and early death, but led to a worse model performance than 
with the full CCI (Table 1). Overall the accuracy of all models 
predicting six-months death was poor with maximum 
AUC=0.62. 
 
 
 
Conclusion: General patient characteristics together with 
comorbidity data, especially the history of a previous 
malignancy, can predict early death, however, prediction 
accuracy is insufficient to select patients to wait and see 
instead of offering SBRT as a curative treatment. 
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